Poor
Not Aligned
Patient Risk:
High
Summary
Several efficacy claims loosely match labeled indication endpoints but expand them beyond the label (e.g., kidney failure, stroke, cardiovascular death phrasing) and include multiple non-label claims; safety and administration details required by the label (potassium monitoring/contraindications/drug interaction constraints) are not addressed. Additional non-prescribing-label claims (patent expiry, manufacturer, pricing) cannot be verified against the provided FDA label excerpts.
Category Scores
Accurate Statements
Finerenone is a non-steroidal mineralocorticoid receptor antagonist.
No support in provided label excerpts.
Finerenone is marketed under the brand name Kerendia.
No support in provided label excerpts.
Finerenone can cause hyperkalemia (high potassium levels).
Supported by 5.1 Hyperkalemia: 'Kerendia can cause hyperkalemia.'
Unsupported Statements
Finerenone (Kerendia) is prescribed to reduce the risk of sustained decline in kidney function in adults with CKD associated with type 2 diabetes.
Label supports reducing risk of 'sustained estimated glomerular filtration rate (eGFR) decline' but the claim states 'kidney function' without the eGFR-specific phrasing; provided excerpts support sustained eGFR decline rather than a general 'kidney function' term.
Finerenone (Kerendia) is prescribed to reduce the risk of kidney failure in adults with CKD associated with type 2 diabetes.
Provided label excerpt lists 'end-stage kidney disease' but does not use the term 'kidney failure.'
Finerenone (Kerendia) is prescribed to reduce the risk of cardiovascular death in adults with CKD associated with type 2 diabetes.
Label excerpt includes 'cardiovascular death' for CKD associated with T2DM, so partially supported; however the claim omits the full list of labeled endpoints and context. Marked as unsupported nuance only for completeness, not a direct contradiction.
Finerenone (Kerendia) is prescribed to reduce the risk of non-fatal heart attacks in adults with CKD associated with type 2 diabetes.
Label excerpt includes 'non-fatal myocardial infarction' but claim uses 'non-fatal heart attacks' (non-label wording).
Finerenone (Kerendia) is prescribed to reduce the risk of stroke in adults with CKD associated with type 2 diabetes.
Provided label excerpt for CKD associated with T2DM does not list stroke as an indicated risk reduction endpoint.
Finerenone works by blocking the effects of excess mineralocorticoid receptor activity that can contribute to kidney and heart damage in individuals with CKD and type 2 diabetes.
Mechanism-of-action description is not included in the provided label excerpts.
Common side effects of finerenone include hyperkalemia (high potassium levels).
Hyperkalemia is supported as a risk (5.1), but the claim characterizes it as a 'common side effect' and does not cite a 'common' frequency from the provided excerpts.
Common side effects of finerenone include hypotension (low blood pressure).
Hypotension is not mentioned in the provided label excerpts.
Common side effects of finerenone include sometimes diarrhea.
Diarrhea is not mentioned in the provided label excerpts.
Finerenone is manufactured by Bayer.
Not supported by the provided label excerpts.
The primary patent for finerenone is set to expire around 2035.
Not supported by the provided label excerpts.
The exact expiry dates for secondary patents and exclusivities for finerenone can vary and are subject to ongoing legal challenges and developments.
Not supported by the provided label excerpts.
A 30-day supply of finerenone without insurance can cost potentially over $500.
Not supported by the provided label excerpts.
A 30-day supply of finerenone (10 mg/20 mg) can cost approximately $521.99.
Not supported by the provided label excerpts.
Prices for finerenone can differ between pharmacies.
Not supported by the provided label excerpts.
Some insurance plans may cover a significant portion of the cost of finerenone, while others may have higher copays or require prior authorization.
Not supported by the provided label excerpts.
Kerendia (finerenone) Savings Card may reduce out-of-pocket cost to $10 per month for commercially insured patients, subject to terms and conditions.
Not supported by the provided label excerpts.
Contradictions
Low
AI Statement
Finerenone (Kerendia) is prescribed to reduce the risk of stroke in adults with chronic kidney disease (CKD) associated with type 2 diabetes.
Label Reference
1 INDICATIONS AND USAGE excerpt for CKD associated with T2DM lists sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure; stroke is not listed.
Important Omissions
No dosing/administration details were provided (e.g., starting dose by eGFR, initiation not recommended for eGFR <25, potassium/eGFR measurement prior to initiation, and potassium/eGFR monitoring at 4 weeks).
Importance:
High
No mention of contraindications (hypersensitivity, concomitant strong CYP3A4 inhibitors, and adrenal insufficiency).
Importance:
High
No mention of the key warning/precaution monitoring and management for hyperkalemia (risk increases with decreasing kidney function; do not initiate if serum potassium >5.0 mEq/L).
Importance:
High
No drug interaction constraints were mentioned (e.g., contraindication with strong CYP3A4 inhibitors).
Importance:
High
Safety Assessment
Potential Patient Risk:
High
The response includes non-label efficacy claims (stroke) and omits label-critical safety requirements (baseline potassium/eGFR assessment, initiation threshold for potassium, contraindications including strong CYP3A4 inhibitors and adrenal insufficiency, and required monitoring/titration).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Efficacy claim includes stroke for CKD+T2DM and multiple safety/administration/contraindication requirements from the label are omitted or not supported by the provided excerpts.
Suggested Improvement
Restrict efficacy endpoints to those listed in the provided 'INDICATIONS AND USAGE' excerpt (e.g., sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, hospitalization for heart failure). Add label-mandated dosing/eligibility and monitoring details (baseline serum potassium and eGFR; do not initiate if potassium >5.0 mEq/L; starting dose by eGFR; potassium/eGFR recheck at 4 weeks and dose adjustment). Include contraindications (strong CYP3A4 inhibitors, hypersensitivity, adrenal insufficiency) and avoid unsupported adverse-effect frequency statements.